Analysts think EDIT stock price could increase by 122%
May 09, 2025, 11:26 AM
39.13%
What does EDIT do
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
11 analysts think EDIT stock price will increase by 121.74%. The current median analyst target is $3.06 compared to a current stock price of $1.38. The lowest analysts target is $1.01 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
